PFIZER19.BK Pfizer Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 5.82%
- Fundamental score
- -
Is PFIZER19.BK undervalued?
Graham numberThe Graham number of Pfizer Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pfizer Inc. fundamental analysis
No fundamental analysis for Pfizer Inc. yet.
Pfizer Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, …
Full company profileFinancial statements of Pfizer Inc. are not available yet.
Pfizer Inc. dividends
Pfizer Inc. has not paid dividends in the last 3 fiscal years.
Who owns Pfizer Inc.
Ownership data of Pfizer Inc. is not available yet.
Pfizer Inc. company profile
- Company name
- Pfizer Inc.
- Ticker
- PFIZER19.BK
- Exchange
- Thailand Exchange
- Sector
- -
- Industry
- -
- Employees
- 75,000
- Fiscal year end
- December
- Address
- 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
- Phone
- 212 733 2323
- Website
- pfizer.com
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer Inc. management
10- Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO · born 1962
- Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development · born 1964
- Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer · born 1966
- Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer · born 1976
- Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer · born 1969
- Mr. Dennis P. HancockExecutive VP & Chief Information Officer
- Ms. Francesca M. DeMartinoChief Investor Relations Officer
- Ms. Payal Sahni BecherChief People Experience Officer & Executive VP · born 1975
- Dr. Michael S. Vincent M.D., Ph.D.Senior VP and Chief Scientific Officer of Inflammation & Immunology
- Dr. Jeffrey Settleman Ph.D.Chief Scientific Officer of Oncology